Ana Paula Queiroz A. Marques

• Lead Caplacizumab global medical strategy
• Collaborate with cross-functional teams to develop and execute Caplacizumab medical plans
• Support lifecycle management activities and integrate evidence-generation strategies to enhance Caplacizumb impact.
• Provide medical expertise and content on regulatory submissions
• Drive stakeholder engagement and oversee data generation efforts to ensure excellence in medical launch readiness.
• Leverage in-depth knowledge of clinical studies to design medical plans grounded in robust scientific evidence.
• Responsible for Global Medical activities including Global advisory boards, medical symposia and congress activities, internal medical trainings etc
• Support development of the caplacizumab risk management strategy and review specific sections of the Periodic benefit-risk assessment report for Capla.
• Review and ensure compliant management of investigator-initiated studies, continuing medical
  education (CME) proposals, and medical education grant applications.
  

• Oversight of multiple products in hemophilia (Fitusiran, BIVV001, Eloctate, Elprolix), iTTP (Caplacizumab), and Cold Aglutinin Disease (Sutimlimab).
  • Execution of global medical strategy into local tactics to achieve goals and exceed KPIs.
  • Training of internal teams (medical, commercial, and sales force) to ensure alignment and scientific excellence.
  • KOL and stakeholder education through active discussions, driving disease and treatment awareness.
  • Identification and development of thought leaders in the therapeutic area, creating and executing a strong KOL engagement plan to build long-term collaborations.
  • Contribution with preparation and submission of dossiers to local Ministries of Health for inclusion of Caplacizumab national health systems.

Key Achievments:

• Executed pre-launch initiatives and led medical launch activities for Caplacizumab achieving critical milestones and successfully implementing the first Early Access Program (Caplacizumab) at Sanofi Brazil.
• Led the development and implementation a diagnostic support program (ADAMTS13) to enhance iTTP diagnosis and ensure proper follow-up of patients.
• Established strategic partnerships with medical societies to foster future collaborations and initiatives aimed at raising awareness and interest in benign hematology.
• Identified and engaged key thought leaders (KOLs), ensuring strong, sustained relationships to advance disease awareness and treatment uptake.

• In charge of Extended Half-Life Factor VIII and Factor IX therapies for hemophilia (Eloctate and Alprolix), acquired by Sanofi through the acquisition of Bioverativ.
• Contributed to the submission of dossiers to the local MoH for the inclusion of Alprolix and Eloctate in the national health system. This involved preparing and providing medical expertise for the submission to CONITEC (National Committee for Health Technology Incorporation),
• Identified and engaged key hemophilia thought leaders, led medical advisory boards and medical education initiatives

•Led the medical strategy for Eculizumab in the PNH indication in Brazil

• Ensured cross-functional teams received education through internal medical trainings and provided medical insights to optimize brand product strategies. S
• Supported the diagnostic program and developed and maintained professional relationships with key opinion leaders and academic centers, ensuring access to current medical and scientific information.
• Facilitated the identification and presentation of research opportunities, assisting in protocol development and administration for supported proposals.

• Led medical strategy for ADVATE (recombinant Factor VIII for Hemophilia A) and ONCASPAR (Pegylated Asparaginase for Acute Lymphoblastic Leukemia).
• Spearheaded the myPKFiT launch in Brazil, a software designed to assist healthcare professionals in applying PK-guided dosing to individualize prophylaxis treatment with ADVATE.
• Engaged with key opinion leaders (KOLs), collected valuable insights, and organized advisory boards and symposiums to optimize product strategies and share relevant scientific information.

• As a general pediatrician at Hospital Municipal Jesus, a prominent public hospital in Rio de Janeiro, I provided comprehensive healthcare to children from infancy through adolescence. My responsibilities included diagnosing and treating common pediatric illnesses, managing chronic conditions, conducting routine health check-ups, and offering preventive care through vaccinations and health education.

• Institute of Hematology Arthur de Siqueira Cavalcanti - HEMORIO is the Main Blood Center in Rio de Janeiro, where I provided specialized care to pediatric patients with hematological diseases as part of a multidisciplinary team,
• Managed and treated a wide range of conditions, including hereditary hemophilia, other rare inherited bleeding disorders, sickle cell disease, thalassemia, leukemia, lymphoma, bone marrow aplasia an others
• Member of the Reference Group for Patients with Coagulopathies in Rio de Janeiro State

• As a pediatric hematologist at Hospital da Lagoa, a renowned public hospital in Rio de Janeiro, I provided specialized care to children with a wide range of benign and oncologic hematologic conditions.